Navigating Cytokine Release Syndrome in Cancer Treatment

This chapter explores the management of cytokine release syndrome (CRS) in patients treated with bispecific antibodies, comparing it to CAR-T therapies. The discussion covers the practical recommendations for CRS management, focusing on the use of dexamethasone versus tocilizumab, along with insights from clinical experiences. Additionally, they address the evolution of treatment protocols and the significance of supportive care, emphasizing the ongoing debate within the medical community regarding optimal management strategies.